Navigation Links
FDA Approves SOMA(R) (carisoprodol) 250 mg
Date:9/17/2007

ick, President & Chief Executive Officer of MedPointe Pharmaceuticals. "While SOMA has a long history in the treatment of discomfort associated with acute, painful musculoskeletal conditions with nearly 50 years on the market, we are pleased to provide a new recommended dose that provides a proven clinical benefit to help relieve the burden of these conditions."

Clinical Trials Demonstrate SOMA 250 mg Efficacy and Favorable Tolerability Profile

FDA approval of SOMA 250 mg was based on the results from two randomized, double-blind, placebo-controlled, multi-site parallel group studies (MP502 and MP505) which included more than 1,300 patients aged 18 to 65 who suffered from acute painful muscle spasm of the lower back. Results from both studies showed that SOMA 250 mg provided significant and rapid relief of back pain compared to placebo (P = 0.0001) with efficacy comparable to SOMA 350 mg.

Results from the studies also showed that SOMA 250 mg provided efficacy comparable to SOMA 350 mg with a more favorable tolerability profile, resulting in fewer discontinuations due to treatment-related adverse events. In the studies, the discontinuation rate due to adverse events for SOMA 250 mg was comparable to placebo and lower than that for SOMA 350 mg (2% versus 2.7% versus 5.4% respectively). The most common side effects associated with SOMA 250 mg in clinical trials included drowsiness (13%), dizziness (8%) and headache (5%). The most common side effects for SOMA 350 mg included drowsiness (17%), dizziness (7%) and headache (3%).

This new recommended dose of SOMA is 250 mg three times a day and at bedtime.

Important Information

SOMA (carisoprodol) is indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults. SOMA should be used for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use has not been established and because acute, painful mu
'/>"/>

SOURCE MedPointe Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. FDA approves Phase 0 trial which tests experimental drugs on humans
2. FDA Approves Contraceptive Ring
3. FDA approves new device to treat womens bleeding disorder
4. FDA Approves New HIV Drug, Viread
5. FDA Approves Birth Control Skin Patch
6. FDA approves surgical gel
7. FDA Approves New Arthritis Drug, Bextra
8. FDA Approves Elidel Cream for Eczema
9. FDA approves drug for rare liver disease
10. FDA approves first pocket-sized EKG machine
11. FDA Approves New Anti-Clotting Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Pass, OR (PRWEB) July 31, 2014 Sales ... 12-percent from 2013 to 2014, according to radio talk show ... has been experiencing rapid growth since 1990. The US economy ... Sharon Kleyne Hour Power of Water radio show, reported this ... Bragg Live Foods, a worldwide manufacturer of organic and natural ...
(Date:7/31/2014)... According to new research report ... by Type (Tofu, Tofu-Based Product, Tempeh, TVP, Seitan, ... Trends & Forecasts to 2019", defines and segments ... and forecasting of the market value of sources, ... also identifies the driving and restraining factors for ...
(Date:7/31/2014)... July 31, 2014 Care Communications, Inc., ... outsourcing firm, has received the Elite Award for “Recruitment, ... Resources, one of twelve elite awards presented as part ... to Work For” 2014 awards competition. This marks ... Elite Award in the competition. CARE has also been ...
(Date:7/31/2014)... July 31, 2014 Daily Gossip reveals in ... help sufferers discover some breakthrough weight loss tips. , ... tips and recommendations are very simple to implement. Users don’t ... foods, with no need to start counting calories. , ... who in fact created a 12 weeks weight loss program ...
(Date:7/31/2014)... 31, 2014 In its latest blog post, ... believes that having family close by during a stay in ... the process is successful, is looking at 10 tips to ... , “Addiction recovery is a lifelong process, and one that ... committed to without compromise,” commented Best Drug Rehabilitation’s CEO ...
Breaking Medicine News(10 mins):Health News:Organic Food Industry Grew 12% in 2013-2014 Reports Sharon Kleyne Hour Power of Water Host 2Health News:Organic Food Industry Grew 12% in 2013-2014 Reports Sharon Kleyne Hour Power of Water Host 3Health News:Meat Substitutes Market Worth $4,622.4 Million by 2019 - New Report by MarketsandMarkets 2Health News:Meat Substitutes Market Worth $4,622.4 Million by 2019 - New Report by MarketsandMarkets 3Health News:Care Communications, Inc. Named an Elite Award Winner Among Top Chicago Employers 2Health News:New Best Drug Rehabilitation Blog Posts Looks at 10 Tips for Coping After Drug or Alcohol Rehab 2
... century, John Snow mapped cases of cholera in Soho, London, ... water pump. Now, in a twenty-first century equivalent, scientists funded ... the latest in gene sequencing technology and global positioning system ... trace its source. Typhoid fever is caused by two ...
... Updated guidelines from the American Academy of Pediatrics (AAP) ... (ADHD) in younger children and in adolescents. Emerging ... in children from ages 4 to 18 (the previous ... 6 to 12). The new guidelines describe the special ...
... , SATURDAY, Oct. 15 (HealthDay News) -- Head injuries are ... a new study finds. Researchers examined data on 52 ... at a pediatric trauma center between 2003 and 2011. The ... 10 and the most common cause of injury was hitting ...
... BOSTON - An in-hospital delay of appendicitis treatment ... likelihood of complications, including perforation and abscess formation; ... according an abstract presented Saturday, Oct. 15 at ... and Exhibition in Boston. In "Missed Opportunities ...
... 14 (HealthDay News) -- Flu activity levels in the United ... get a flu shot, the U.S. Centers for Disease Control ... for the 2011-2012 flu season, the federal agency also said ... the U.S. supply is projected to be at an all-time ...
... One in six people in the United States is affected ... multiple sclerosis, and more research is required to find new ... mark its 20th anniversary, the foundation has released a video ... ongoing research. "Brain disease is in the news every ...
Cached Medicine News:Health News:Google Earth typhoid maps reveal secrets of disease outbreaks 2Health News:Google Earth typhoid maps reveal secrets of disease outbreaks 3Health News:AAP expands ages for diagnosis and treatment of ADHD in children 2Health News:Delayed pediatric appendicitis treatment linked to complications, and even death 2Health News:Get Your Flu Shot Now, CDC Urges 2Health News:Foundation Aims to Raise Awareness of Brain Diseases 2
(Date:7/30/2014)... Germany , July 30, 2014  invendo ... and computer-assisted ("robotic") colonoscopy system, today announced the appointment ... medical device executive, as a new member of its ... highly respected global visionary in the medical device industry. ... and Chief Executive Officer at Given Imaging Ltd. (NASDAQ/TASE: ...
(Date:7/30/2014)... TARRYTOWN, N.Y. and PARIS ... REGN ) and Sanofi (EURONEXT: SAN and ... new Phase 3 ODYSSEY trials of alirocumab in people ... greater percent reduction from baseline in low-density lipoprotein cholesterol ... comparator.  Alirocumab is an investigational monoclonal antibody targeting PCSK9 ...
(Date:7/30/2014)... VEGAS , July 30, 2014  DigiPath, Inc. ... that is expanding into the cannabis testing and education ... in its business and affairs not previously disclosed or, ... the recent unusual market action. "We have ... over the last three trading days," said Steve ...
Breaking Medicine Technology:invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 2invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8DigiPath No New Corporate Developments 2
... patient tracking and billing. ... complete Handheld application, a ... complete CPT™ and ICD-9-CM ... AMA. Designed for any ...
... ToolBox is an advanced medical ... Emergency, Pediatric Dosing and Critical ... is a logical complement to ... as the Daviss Drug Guide, ...
... the handheld version of ... drug interaction analyzer covering ... generic drugs. iFacts™ enables ... to accurate and reliable ...
A handy, quick reference for physicians, nurses, and other health care providers treating cancer patients....
Medicine Products: